aap Implantate AG

Earnings Release • May 31, 2001

News Details

Ad-hoc | 31 May 2001 03:12

aap Implantate AG english

Ad hoc announcement transmitted by DGAP. The issuer is solely responsible for the content of this announcement. ——————————————————————————– Substantial sales growth at aap Implantate Consolidated sales up 84% to DM 5.8 million / EBITDA up 128% ex stock options / Preproduction R&D and marketing costs affect operating result aap Implantate AG’s substantial sales growth continued in the first quarter of 2001. Sales were up 84% on the year to DM 5.8 million from roughly DM 3.2 million. In Germany, sales growth was roughly 115%. Total operating performance increased by 64% on the year to DM 7.5 million from roughly DM 4.6 million. EBITDA ex stock options was up 128% to DM 1.1 million (previous year: DM 463 thousands). Disregarding acquisition-related depreciations totaling roughly DM 789 thousands and stock options totaling DM 406 thousands, results are as follows: Operating result up by roughly 237% to DM 435 thousands from DM 129 thousands. DVFA/SG consolidated earnings in the review period DM 47 thousands (previous year: DM 23 thousands). DVFA/SG earnings per share DM 0.01 (previous year: DM 0.01). DVFA/SG cash earnings for the quarter increased by roughly 294% to DM 1.5 million from DM 385 thousands. A main hallmark of the first quarter was further development of the new BFS (Biorigid Femur System) and TSS (Trauma Shoulder System) products and sales and marketing costs for them. Operating expenditure also reflected high upfront costs for the market launch of aap subsidiary Coripharm’s bone substitute products and the cost of setting up a sales network in the Chinese market. end of ad hoc announcement (c) DGAP 31.05.2001 Issuer’s information/explanatory remarks concerning this ad hoc announcement: After acquisition-related depreciations and stock options the figures are as follows: Operating result down to minus DM 760 thousands from DM 129 thousands in the first quarter of 2000. DVFA/SG consolidated result for the review period minus DM 694 thousands (previous year: DM 23 thousands). DVFA/SG earnings per share minus DM 0.15 (previous year: DM 0.01). DVFA/SG cash earnings up on the year to DM 774 thousands from DM 385 thousands. The first quarter of 2001 thus reflects the usual course of the fiscal year at aap. While moderate sales and earnings growth is typical of the first two quarters, we expect above-average increase in sales and earnings in the third and fourth quarters. ——————————————————————————– WKN: 506660; Index: Listed: Neuer Markt Frankfurt; Freiverkehr in Berlin, Bremen, Düsseldorf, Hamburg, Hannover, München und Stuttgart 310312 Mai 01